ivermectin
exelpet products a div of mars australia pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
virbac (australia) pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
rwr veterinary products pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
abbey laboratories pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
chemvet australia pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
nutrien ag solutions limited - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
titan ag pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
ivermectin
abbey laboratories pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent
soolantra ivermectin 10 mg/g cream tube
galderma australia pty ltd - ivermectin, quantity: 10 mg/g - cream - excipient ingredients: glycerol; isopropyl palmitate; carbomer copolymer (type b); dimeticone 20; disodium edetate; citric acid monohydrate; cetyl alcohol; stearyl alcohol; ceteareth-20; sorbitan stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; phenoxyethanol; propylene glycol; oleyl alcohol; sodium hydroxide; purified water - soolantra is indicated for the topical treatment of inflammatory lesions of rosacea (papulo-pustular) in adult patients 18 years and over.
ivermectin tablet
bryant ranch prepack - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin is indicated for the treatment of the following infections: ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite strongyloides stercoralis . this indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (see clinical pharmacology, clinical studies). ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite onchocerca volvulus . this indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of west africa. the comparative studies used diethylcarbamazine citrate (dec-c). note: ivermectin has no activity against adult onchocerca volvulus parasites. the adult parasites reside in subcutaneous nodules which are infrequently palpable. surgical excision of these nodules (nodulectomy) may b